netFormulary Joint Medicines Formulary NHS
Airedale NHS Foundation Trust
Airedale, Wharfedale and Craven CCG		  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:
Unless explicitly stated, any brand names included in brackets next to a drug's generic name are there solely to aid searching and identification, and should not be considered to limit use to that specific brand.  
Chapter Links...
Link   Haematology and Oncology Protocols and Guidelines
Link   DSU: Medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed? (March 2019)
 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
 link Link    NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia (June 2018)
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Arsenic trioxide
08.01.05  Expand sub section  Bevacizumab
08.01.05  Expand sub section  Bexarotene to top
08.01.05  Expand sub section  Bortezomib
08.01.05  Expand sub section  Cetuximab
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide
08.01.05  Expand sub section  Hydroxycarbamide to top
08.01.05  Expand sub section  Ipilimumab
08.01.05  Expand sub section  Mitotane
08.01.05  Expand sub section  Panitumumab
08.01.05  Expand sub section  Pentostatin
08.01.05  Expand sub section  Platinum compounds to top
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine
08.01.05  Expand sub section  Protein kinase inhibitors
Abemaciclib tablets  (Verzenios® )
View adult BNF View SPC online View childrens BNF  Track Changes 		Restricted Drug Restricted
Red
BlueTeq
  • Abemaciclib tablets (Verzenios®)

Consultant Oncologist use only.

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (February 2019)
Link  NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (May 2019)
Link  NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (May 2019)
 
Cytotoxic Drug Afatinib (Giotrif®)
View adult BNF View SPC online View childrens BNF  Track Changes 		Restricted Drug Restricted
Red
  • Afatinib Tablets (Giotrif®)


 
Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (April 2014)
 
Cytotoxic Drug Alectinib capsules  (Alecensa®)
View adult BNF View SPC online View childrens BNF  Track Changes 		Restricted Drug Restricted
Red
BlueTeq
  • Alectinib Capsules (Alecensa®)

Consultant Medical Oncologist use only.

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (August 2018)
 
Cytotoxic Drug Bosutinib (Bosulif®)
View adult BNF View SPC online View childrens BNF  Track Changes 		Restricted Drug Restricted
Red
Cancer Drugs Fund
BlueTeq
  • Bosutinib Tablets

    Consultant Haematologist use only.

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 

 
Link  MHRA Drug Safety Update: BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation(May 2016)
Link  NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia (August 2016)
 
Cytotoxic Drug Brigatinib tablets (Alunbrig®)
View adult BNF View SPC online View childrens BNF  Track Changes 		Restricted Drug Restricted
Red
  • Brigatinib tablets (Alunbrig®)

Consultant Medical Oncologist use only.

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  NICE TA571:Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (March 2019)
 
Cytotoxic Drug Ceritinib capsules  (Zykadia®)
View adult BNF View SPC online View childrens BNF  Track Changes 		Restricted Drug Restricted
Red
BlueTeq
  • Ceritinib Capsules (Zykadia®)


Consultant Medical Oncologist use only.

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (June 2016)
Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer (January 2018)
 
Cytotoxic Drug Dacomitinib (Vizimpro®)
View adult BNF View SPC online View childrens BNF  Track Changes 		Restricted Drug Restricted
Red
BlueTeq
  • Dacomitinib Tablets

 

Consultant Oncology use only

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (August 2019)
 
Cytotoxic Drug Erlotinib
View adult BNF View SPC online View childrens BNF  Track Changes 		Restricted Drug Restricted
Red
  • Erlotinib Tablets


 
Link  NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer [Not recommended] (June 2011)
Link  NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (June 2012)
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (December 2015)
 
Cytotoxic Drug Everolimus (Afinitor®)
View adult BNF View SPC online View childrens BNF  Track Changes 		Restricted Drug Restricted
Red
BlueTeq
  • Everolimus Tablets (Afinitor®)

    Blueteq® registration and approval for use is required for this product before it may be dispensed.
 
Link  NICE TA 449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (June 2017) [Specialist Centre Only]
Link  NICE TA219: Everolimus for the second-line treatment of advanced renal cell carcinoma (April 2011) NOT RECOMMENDED [Specialist Centre Only]
Link  NICE TA348: Everolimus for preventing organ rejection in liver transplantation (July 2015)
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (December 2016)
Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment (Feb 2017) [Specialist Centre Only]
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (January 2018) [Specialist Centre Only]
 
Cytotoxic Drug Gefitinib
View adult BNF View SPC online View childrens BNF  Track Changes 		Restricted Drug Restricted
Red
  • Gefitinib Tablets

 
Link  NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (July 2010)
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (December 2015)
 
Cytotoxic Drug Idelalisib (Zydelig®)
View adult BNF View SPC online View childrens BNF  Track Changes 		Restricted Drug Restricted
Red
  • Idelalisib Tablets


 
Link  EMA recommends new safety measures for Zydelig (March 2016)
Link  MHRA Drug Safety Update: Idelalisib (Zydelig): updated indications and advice on minimising the risk of infection (September 2016)
Link  NICE TA359 Idelalisib for treating chronic lymphocytic leukaemia (October 2015)
Link  NICE TA604: Idelalisib for treating refractory follicular lymphoma (October 2019)
 
Cytotoxic Drug Imatinib
View adult BNF View SPC online View childrens BNF  Track Changes 		Restricted Drug Restricted
Red
  • Imatinib Tablets


 
Link  MHRA Drug Safety Update: BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation (May 2016)
Link  NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (November 2010)
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (December 2016)
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (December 2016)
Link  NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia (January 2016)
Link  NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (November 2010)
 
Cytotoxic Drug Larotrectinib 20mg/mL oral solution  (Vitrakvi®)
View adult BNF View SPC online View childrens BNF  Track Changes 		Restricted Drug Restricted
Red
Cancer Drugs Fund
BlueTeq
  • Larotrectinib 20mg/mL oral solution (Vitrakvi®)

    Consultant Medical Oncologist use only.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours (May 2020)
 
Cytotoxic Drug Lorlatinib (Lorviqua®)
View adult BNF View SPC online View childrens BNF  Track Changes 		Restricted Drug Restricted
Red
NHS England
BlueTeq
  • Lorlatinib Tablets (Lorviqua®)

         Consultant Medical Oncologist use only.

      Blueteq® registration and approval for use is required for this product before it may be        dispensed.

 
Link  NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (May 2020)
 
Cytotoxic Drug Nilotinib (Tasigna®)
View adult BNF View SPC online View childrens BNF  Track Changes 		Restricted Drug Restricted
Red
BlueTeq
  • Nilotinib Tablets

    Blueteq® registration and approval for use is required for this product before it may be dispensed.
 
Link  MHRA Drug Safety Update: BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation (May 2016)
Link  NICE TA241: Dasatinib, high-dose imatinib and nilotinib for use in patients who are resistant or intolerant to imatinib (January 2012)
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (December 2016)
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (December 2016)
 
Cytotoxic Drug Nintedanib capsules  (Vargatef®)
View adult BNF View SPC online View childrens BNF  Track Changes 		Restricted Drug Restricted
Red
  • Nintedanib Capsules (Vargatef®)


 
Link  NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (July 2015)
Link  NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis (January 2016)
 
Cytotoxic Drug Osimertinib mesylate ( Tagrisso®)
View adult BNF View SPC online View childrens BNF  Track Changes 		Restricted Drug Restricted
Red
Cancer Drugs Fund
BlueTeq
  • Osimertinib Tablets

Consultant Medical Oncologist use only.

 

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (October 2016)
 
Cytotoxic Drug Palbociclib (Ibrance®)
View adult BNF View SPC online View childrens BNF  Track Changes 		Restricted Drug Restricted
Red
BlueTeq
  • Palbociclib capsules
  • Palbociclib capsules with fulvestrant injection


Blueteq® registration and approval for use is required for this product before it may be dispensed.

 

 
Link  NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (December 2017)
Link  NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (January 2020)
 
Cytotoxic Drug Ribociclib (Kiskali®)
View adult BNF View SPC online View childrens BNF  Track Changes 		Restricted Drug Restricted
Red
BlueTeq
  • Ribociclib Tablets

    Blueteq® registration and approval for use is required for this product before it may be dispensed.
 
Link  NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (December 2017)
Link  TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (August 2019)
 
Cytotoxic Drug Ruxolitinib (Jakavi®)
View adult BNF View SPC online View childrens BNF  Track Changes 		Restricted Drug Restricted
Red
Cancer Drugs Fund
  • Ruxolitinib Tablets


 
Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (March 2016)
 
08.01.05  Expand sub section  Taxanes
08.01.05  Expand sub section  Topoisomerase I inhibitors to top
08.01.05  Expand sub section  Trabectedin
08.01.05  Expand sub section  Trastuzumab
08.01.05  Expand sub section  Tretinoin
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
 Display tracking information
click to search medicines.org.uk
 Link to adult BNF
click to search medicines.org.uk
 Link to children's BNF
click to search medicines.org.uk
 Link to SPCs
Cytotoxic Drug
 Cytotoxic Drug
CD
 Controlled Drug
High Cost Medicine
 High Cost Medicine
Cancer Drugs Fund
 Cancer Drugs Fund
NHSE
 NHS England
Homecare
 Homecare
CCG
 CCG

Traffic Light Status Information

Status Description

Green

 Green - Drugs suitable for generalised use in accordance with position summary. Inform primary care of need to prescribe using a TTO chart if in patient or Treatment Advice Note (TAN) if Outpatient.   

Amber

 Amber - these drugs require specialist initiation or recommendation  

Amber SCG

 Amber Share Care - Drugs suitable for generalist use, in accordance with position summary, normally following specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place status reverts to red.  

Red

 Red - Drugs for specialist use only, in accordance with position summary. GP’s should not be asked to prescribe these products.  

Red ULM

 Red ULM - Unlicensed medicines for specialist use only, in accordance with position summary. GP’s should not be asked to prescribe these products.  

Grey

 Grey drugs - No formal commissioning position. Check appropriate CCG /NHSE commissioning list or contact CCG/NHSE Medicines Management team for advice. Fill in individual funding request for appropriate CCG/NHSE. This will need to be signed by the Chief Pharmacist and a copy of the relevant DTC submission attached.   

Black

 Black - Drugs not routinely commissioned so should not usually be prescribed  

netFormulary